| Literature DB >> 26020948 |
Shotaro Ide1, Shigeki Nakamura2, Yoshihiro Yamamoto3, Yoshihisa Kohno4, Yuichi Fukuda5, Hideki Ikeda6, Eisuke Sasaki7, Katsunori Yanagihara8, Yasuhito Higashiyama9, Kohji Hashiguchi10, Yoji Futsuki11, Yuichi Inoue12, Kiyoyasu Fukushima13, Naofumi Suyama11, Shigeru Kohno14.
Abstract
BACKGROUND AND OBJECTIVES: Recent reports indicate that the incidence of nontuberculous mycobacterial-lung disease (NTM-LD) is increasing. This study aimed to investigate the epidemiology and clinical features of NTM-LD patients in Nagasaki prefecture, Japan to identify the negative prognostic factors for NTM-LD in Japan.Entities:
Mesh:
Year: 2015 PMID: 26020948 PMCID: PMC4447365 DOI: 10.1371/journal.pone.0128304
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Flowchart of patient selection.
Fig 2Annual incidence of NTM-LD between 2001 and 2009 in Nagasaki, Japan.
(A) Incidence of NTM-LD and all types of tuberculosis in all patients. (B) Incidence in male patients. (C) Incidence in female patients.
Isolates detected in 975 NTM-LD patients.
| Isolate | Number (%) |
|---|---|
|
| 432 (44.3) |
|
| 415 (42.6) |
|
| 30 (3.1) |
| MAC | 24 (2.5) |
|
| 20 (2.1) |
|
| 20 (2.1) |
|
| 7 (0.7) |
|
| 3 (0.3) |
|
| 3 (0.3) |
|
| 2 (0.2) |
|
| 2 (0.2) |
|
| 2 (0.2) |
|
| 2 (0.2) |
|
| 1 (0.1) |
| PMI except for MAC | 7 (0.7) |
| Not identified | 5 (0.5) |
MAC, Mycobacterium avium-intracellulare complex; PMI, polymicrobial infection
*Identified using 16S rRNA.
Fig 3Isolates detected in NTM-LD patients between 2001 and 2009 in Nagasaki, Japan.
RGM, rapid growing mycobacteria.
Fig 4Geographic variation in isolates detected in NTM-LD patients.
Nine patients were residents of another prefecture. Map was obtained from the Geospatial Information Authority of Japan (http://www.gsi.go.jp/ENGLISH/index.html). MAC, Mycobacterium avium-intracellulare complex.
Fig 5Geographic variation in radiographic patterns in NTM-LD patients.
Four patients were residents of another prefecture. NB, nodular-bronchiectatic pattern; CAV, cavitary pattern.
Underlying respiratory diseases of NTM-LD.
| Total | Male | Female | P value | ||||
|---|---|---|---|---|---|---|---|
| 601 | (%) | 182 | (%) | 419 | (%) | ||
| Underlying lung disease | 189 | (31.4) | 90 | (49.5) | 99 | (23.4) | <0.0001 |
| History of tuberculosis | 81 | (13.5) | 35 | (19.2) | 46 | (11.0) | 0.0065 |
| COPD | 35 | (5.8) | 22 | (12.1) | 13 | (3.1) | <0.0001 |
| Lung cancer | 33 | (5.5) | 17 | (9.3) | 16 | (3.8) | 0.0063 |
| Interstitial lung disease | 24 | (4.0) | 13 | (7.1) | 11 | (2.6) | 0.0094 |
| Fungal infection | 15 | (2.5) | 9 | (4.9) | 6 | (1.4) | 0.0112 |
| History of lung surgery | 13 | (2.2) | 9 | (4.9) | 4 | (1.0) | 0.002 |
| Bronchial asthma | 11 | (1.8) | 4 | (2.2) | 7 | (1.7) | 0.6578 |
| Chronic bronchitis | 9 | (1.5) | 5 | (2.7) | 4 | (1.0) | 0.0964 |
| Silicosis | 8 | (1.3) | 8 | (4.4) | 0 | (0.0) | <0.0001 |
| Bronchiectasis | 2 | (0.3) | 1 | (0.5) | 1 | (0.2) | 0.5433 |
| Pulmonary sarcoidosis | 2 | (0.3) | 1 | (0.5) | 1 | (0.2) | 0.5433 |
COPD, Chronic Obstructive Pulmonary Disease.
Causes of immunodeficiency.
| N = 601 (%) | ||
|---|---|---|
| Steroid administration | 31 | (5.2) |
| Methotrexate (MTX) administration | 4 | (0.7) |
| Immunosuppressant administration except MTX | 8 | (1.3) |
| Steroid and immunosuppressant administration | 10 | (1.7) |
| Diabetes | 54 | (9.0) |
| Collagen disease | 30 | (5.0) |
| Malignant disease | 44 | (7.3) |
| Chronic kidney disease | 9 | (1.5) |
| Chronic hepatic disease | 22 | (3.7) |
Characteristics and 1-year prognosis of NTM-LD patients.
| Total (%) | Stability (%) | Deterioration (%) | P value | |
|---|---|---|---|---|
| No. of patients | 204 | 159 (77.9) | 45 (22.1) | |
| Age | 69.9 ± 11.6 | 69.2 ± 11.0 | 73.3 ± 11.3 | 0.00315 |
| Male/female | 61/143 | 46/113 | 15/30 | 0.3243 |
| BMI < 18.5 kg/m2 | 48 (23.5) | 33 (20.8) | 15 (33.3) | 0.0355 |
| CRP level (mg/dL) | 0.85 ± 2.13 | 0.52 ± 1.21 | 1.49 ± 3.08 | 0.1431 |
| Smoking pack-years ≥ 20 | 18 (8.8) | 12 (7.5) | 6 (13.3) | 0.0582 |
| CAM dose (mg) | 565.2 ± 214.7 | 573.5 ± 192.0 | 542.9 ± 198.9 | 0.6369 |
| Underlying lung disease | 65 (31.9) | 45 (28.3) | 20 (44.4) | 0.0089 |
| CAV | 25 (12.3) | 15 (9.4) | 10 (22.2) | 0.006 |
BMI, body mass index; CRP, C-reactive protein; CAM, clarithromycin; CAV, cavitary pattern on chest radiographs.
*Includes history of tuberculosis, chronic obstructive pulmonary disease, lung cancer, interstitial lung disease, asthma, and silicosis.